All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

  TRANSLATE

The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Eduardo Rego | EHA 2018 | Overcoming the main challenges for treating AML/APL in developing countries

By Eduardo Rego

Share:

Featured:

Eduardo RegoEduardo Rego

Jun 15, 2018


Eduardo Rego from University of São Paulo, São Paulo, BR, comments on the challenges facing physicians treating of acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) at the 2018 European Hematology Association (EHA) meeting. He highlighted that the delay in approval of novel agents and cost are some of the main problems facing physicians in developing countries. 

Overcoming the main challenges for treating AML/APL in developing countries